DANIEL RAPPAPORT: Open Payments
NPI 1003868381 · WHITEHALL, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$479 in 29 payments from 16 companies in 2025. Trend: 2023 $664 · 2024 $493 · 2025 $479
Food & beverage: $479
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $69 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Amgen Inc. | 3 | $47 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $36 |
| ABBVIE INC. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| Madrigal Pharmaceuticals | 2 | $30 |
| Lilly USA, LLC | 2 | $30 |
| Astellas Pharma US Inc | 1 | $22 |
Products named: NEXLETOL, JARDIANCE, VRAYLAR, REXULTI, OTEZLA, XIFAXAN, REZDIFFRA, ZEPBOUND.
Industry payments across PA — which companies pay providers there.
